The information provided in this section is intended expressly for healthcare professionals in the United States. Click “OK” to enter if you are a US healthcare professional.
The recommended starting dose is 160 mg STIVARGA (four 40-mg tablets) taken orally once daily for the first 3 weeks, followed by a 1-week treatment break.1
Regorafenib (STIVARGA®) dose escalation schedule in mCRC
National Comprehensive Cancer Network (NCCN®) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
*The study supporting the dose-escalation schedule has not been reviewed by the FDA. The study was a randomized, phase 2, US-based trial through the Academic and Community Cancer Research United (ACCRU) research network that looked at the proportion of patients who completed 2 cycles of STIVARGA and initiated a third cycle (N=116). The efficacy of the alternative dosing schedule cannot be compared to the efficacy of other trials. 4
†Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.2, 3
AE, adverse event; FDA, US Food and Drug Administration.